Aurinia Pharmaceuticals hits new 52-week high, shares extend strong NASDAQ run
22.06.2026 - 19:23:46 | ad-hoc-news.de
By Thomas Klein, Operations & Strategy desk. Reviewed prior to publication on 2026-06-22, 19:18.
Aurinia Pharmaceuticals (CA05156H1070) has pushed to a fresh 52-week high on the NASDAQ, with the shares touching 17.44 US dollars and recently trading around 17.54 dollars according to Investing.com data.Investing.com highlights the new 52-week peak The move places the biotech name firmly in focus within the NASDAQ Biotechnology Index.
What the latest high shows
At the intraday mark cited by Investing.com, Aurinia Pharmaceuticals shares were up roughly 110 percent over twelve months, with a one-year performance of 110.22 percent and a market capitalization near 2.12 billion US dollars.The Investing.com report details performance and valuation Revenues are reported at about 298.3 million US dollars, growing 20.6 percent year-on-year, while the article cites a high earnings multiple around 75 times.
According to the same analysis, the stock still screens as undervalued against an internal fair value estimate on InvestingPro, despite the strong price advance and the new 52-week high.InvestingPro’s valuation view accompanies the 52-week high note The report also emphasizes that Aurinia currently holds more cash than debt, underlining a solid balance sheet profile for a mid-cap biotech issuer.
Management and deal activity in focus
Beyond the share price move, Aurinia Pharmaceuticals has seen notable corporate developments, including a management transition at the top of the company.StockTitan summarizes recent Aurinia management news According to a recent business update cited in StockTitan, board chair Tang has been appointed as the new chief executive officer, taking the role without salary, bonuses or equity compensation.
The leadership change follows the departure of former CEO Peter Greenleaf, who is set to remain as a consultant during the handover period.The same overview references the planned Greenleaf advisory role For investors in NASDAQ-listed biopharmaceutical peers such as Vertex Pharmaceuticals or Biogen, governance shifts of this kind are often seen as signals on strategic direction and capital allocation priorities.
All news and analysis on the Aurinia Pharmaceuticals shares
Further corporate releases, analyst views and price data on Aurinia Pharmaceuticals can be found in the dedicated topic section and on the company’s investor relations page.
How Aurinia makes its money
Aurinia Pharmaceuticals generates the bulk of its revenue from Lupkynis, an FDA-approved oral calcineurin inhibitor indicated for adults with active lupus nephritis, a serious kidney manifestation of systemic lupus erythematosus.The company’s product information details Lupkynis as its lead asset The drug is marketed in the United States in partnership with Otsuka and provides a recurring revenue stream tied to prescription volumes and reimbursement levels.
Where the Aurinia stock trades today
The Aurinia Pharmaceuticals shares (CA05156H1070) trade on NASDAQ under the ticker AUPH, with the last quoted price around 17.54 US dollars and a 52-week high print at 17.44 dollars on 2026-06-22, according to Investing.com.
Key data on the Aurinia Pharmaceuticals shares
- Company: Aurinia Pharmaceuticals Inc.
- ISIN: CA05156H1070
- WKN: A1W7D4
- Ticker: AUPH
- Trading venue: NASDAQ
- Price (as of 2026-06-22, 09:46): 17.54 USD
- Market cap: 2.12 billion USD (as of 2026-06-22)
- Sector / industry: Biotechnology / Biopharmaceuticals
- Index membership: NASDAQ Biotechnology Index
- Next earnings date: not officially scheduled
This article provides factual information and does not contain investment advice or recommendations. Investors should conduct their own research and, where appropriate, consult a qualified financial advisor before making investment decisions.
